Welireg — CareFirst (Caremark)

Initial criteria

• Disease is advanced
• Member has been previously treated with a PD-1 or PD-L1 inhibitor (e.g., nivolumab [Opdivo], pembrolizumab [Keytruda]) and a VEGF-TKI (e.g., axitinib [Inlyta], cabozantinib [Cabometyx], lenvatinib [Lenvima])

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months